{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_50984"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_50984","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"PRECLINICAL DEVELOPMENT OF ALPHA-PARTICLE THERAPEUTICS","abstract":"Internal radiation therapy is an alternative method to external beam radiation therapy for the treatment of cancer. Alpha (α)-particle based internal radiation therapy methods are being explored to improve the efficacy and toxicity compared to using beta (β-)-emitting isotopes. Two α-particle delivery platforms were developed; Pb-212-GlaS-Fc, which utilizes a systemic targeted approach, and Bi-212-MAA, which is a short-lived locoregionally delivered embolic radiopharmaceutical. Both of these radiopharmaceuticals were shown to be efficacious in treatment of cancer cells and be potential clinic therapeutics. Further, Bi-212-MAA was used as a platform to understand cellular and molecular responses of cancer to α-particle radiation. It was found that cancer cells are unable to utilize certain canonical radiation resistant responses, such as cell cycle control, when treated with α-particles. Additionally, cytokine production was dysregulated in these cells after treatment. These findings indicate that these two new delivery strategies have potential for translation to the clinic and that Bi-212-MAA can be used as a tool to elucidate additional molecular effects of α-particles on cancer cells.","abstract_html":"Internal radiation therapy is an alternative method to external beam radiation therapy for the treatment of cancer. Alpha (α)-particle based internal radiation therapy methods are being explored to improve the efficacy and toxicity compared to using beta (β-)-emitting isotopes. Two α-particle delivery platforms were developed; Pb-212-GlaS-Fc, which utilizes a systemic targeted approach, and Bi-212-MAA, which is a short-lived locoregionally delivered embolic radiopharmaceutical. Both of these radiopharmaceuticals were shown to be efficacious in treatment of cancer cells and be potential clinic therapeutics. Further, Bi-212-MAA was used as a platform to understand cellular and molecular responses of cancer to α-particle radiation. It was found that cancer cells are unable to utilize certain canonical radiation resistant responses, such as cell cycle control, when treated with α-particles. Additionally, cytokine production was dysregulated in these cells after treatment. These findings indicate that these two new delivery strategies have potential for translation to the clinic and that Bi-212-MAA can be used as a tool to elucidate additional molecular effects of α-particles on cancer cells.","abstract_has_math":false,"creators":["Kauffman, Nathan"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Zinn, Kurt R.","Neubig, Richard","Alessio, Adam","Magestro, Leanne"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-11-18T18:57:50Z","subjects":["Biomedical engineering"],"languages":["English"],"rights":["Attribution 4.0 International"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:50984","local:Kauffman_grad.msu_0128D_20019"],"render_values":[{"text":"etd:50984","href":null,"code":true},{"text":"local:Kauffman_grad.msu_0128D_20019","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/wdn0-tt47","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/wdn0-tt47","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_50984","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Zinn, Kurt R.","Neubig, Richard","Alessio, Adam","Magestro, Leanne"]},{"key":"dc:creator","label":"Author","values":["Kauffman, Nathan"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biomedical engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution 4.0 International"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:50984","local:Kauffman_grad.msu_0128D_20019","https://doi.org/doi:10.25335/wdn0-tt47"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Internal radiation therapy is an alternative method to external beam radiation therapy for the treatment of cancer. Alpha (α)-particle based internal radiation therapy methods are being explored to improve the efficacy and toxicity compared to using beta (β-)-emitting isotopes. Two α-particle delivery platforms were developed; Pb-212-GlaS-Fc, which utilizes a systemic targeted approach, and Bi-212-MAA, which is a short-lived locoregionally delivered embolic radiopharmaceutical. Both of these radiopharmaceuticals were shown to be efficacious in treatment of cancer cells and be potential clinic therapeutics. Further, Bi-212-MAA was used as a platform to understand cellular and molecular responses of cancer to α-particle radiation. It was found that cancer cells are unable to utilize certain canonical radiation resistant responses, such as cell cycle control, when treated with α-particles. Additionally, cytokine production was dysregulated in these cells after treatment. These findings indicate that these two new delivery strategies have potential for translation to the clinic and that Bi-212-MAA can be used as a tool to elucidate additional molecular effects of α-particles on cancer cells.","Thesis (Ph.D.)--Michigan State University. Comparative Medicine and Integrative Biology - Doctor of Philosophy, 2023","Includes bibliographical references"]},{"key":"dc:format","label":"Dc Format","values":["88 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["PRECLINICAL DEVELOPMENT OF ALPHA-PARTICLE THERAPEUTICS"]}]}],"canonical_facts":{"dc:contributor":["Zinn, Kurt R.","Neubig, Richard","Alessio, Adam","Magestro, Leanne"],"dc:creator":["Kauffman, Nathan"],"dc:date":["2023"],"dc:description":["Internal radiation therapy is an alternative method to external beam radiation therapy for the treatment of cancer. Alpha (α)-particle based internal radiation therapy methods are being explored to improve the efficacy and toxicity compared to using beta (β-)-emitting isotopes. Two α-particle delivery platforms were developed; Pb-212-GlaS-Fc, which utilizes a systemic targeted approach, and Bi-212-MAA, which is a short-lived locoregionally delivered embolic radiopharmaceutical. Both of these radiopharmaceuticals were shown to be efficacious in treatment of cancer cells and be potential clinic therapeutics. Further, Bi-212-MAA was used as a platform to understand cellular and molecular responses of cancer to α-particle radiation. It was found that cancer cells are unable to utilize certain canonical radiation resistant responses, such as cell cycle control, when treated with α-particles. Additionally, cytokine production was dysregulated in these cells after treatment. These findings indicate that these two new delivery strategies have potential for translation to the clinic and that Bi-212-MAA can be used as a tool to elucidate additional molecular effects of α-particles on cancer cells.","Thesis (Ph.D.)--Michigan State University. Comparative Medicine and Integrative Biology - Doctor of Philosophy, 2023","Includes bibliographical references"],"dc:format":["88 pages","application/pdf"],"dc:identifier":["etd:50984","local:Kauffman_grad.msu_0128D_20019","https://doi.org/doi:10.25335/wdn0-tt47"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["Attribution 4.0 International"],"dc:subject":["Biomedical engineering"],"dc:title":["PRECLINICAL DEVELOPMENT OF ALPHA-PARTICLE THERAPEUTICS"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T18:57:50Z"}